Capping Innovation with Life
CAP
ANALOG
View More
MS₁Cap
MS₂Cap
MS₃Cap
MS₄Cap
MSCap Research Data
Luciferase Expression in HEK293 Cell
Luciferase Expression
Research data: Exvivo study on tumor growth inhibition
This result was obtained under specific research conditions and is provided for research reference only. It does not represent approved therapeutic claims.
mRNA Plarform Technology
CAPPING
TECHNOLOGY
Capping technology plays a pivotal role in the development
of mRNA therapeutics by stabilizing transcripts, protecting them
from exonuclease degradation, and ensuring efficient ribosomal
recognition.
MODIFIED
NUCLEOSIDE
Modified nucleosides are essential for enhancing the performance
of mRNA therapeutics. By reducing innate immune activation and
increasing transcript stability, they enable higher translational efficiency
and prolonged protein expression.
3’END
MODIFICATION
3’ end modification is a critical strategy to enhance the stability and
durability of mRNA transcripts. By protecting against exonuclease
degradation and optimizing poly(A) tail structures, these modifications
prolong mRNA half-life and sustain protein expression.
